Su CC, et al. - Researchers conducted this short-term longitudinal study to prospectively assess the impact of benzalkonium chloride (BAK)-preserved latanoprost on ocular surface damage and identify the associated risk factors among treatment-naive glaucoma patients. The basal Schirmer’s test outcomes, corneal Oxford staining score, non-invasive keratograph tear-breakup time, oculus hyperemia index score (objective metrics), and ocular surface disease index (OSDI) questionnaire (subjective metric) were assessed at baseline, 1 month, and 4 months after receiving latanoprost eye drops. Participants in the study were 44 patients (74 eyes). Through decreased basal tear secretion, preserved latanoprost eye drops affected ocular surface changes in glaucoma patients. In susceptible glaucoma patients with decreased tear secretion and impaired tear-film stability, artificial tears represent an early intervention.